Search Results
Your search for ,led matches 5950 pages
Showing 1351 - 1400President Biden Appoints Cancer Panel Members, and Cancer Cabinet Unveils Priority Actions
On July 13, President Joe Biden announced his intent to appoint Mitchel Berger, MD; Carol Brown, MD; and Elizabeth M. Jaffee, MD, to the President’s Cancer Panel. The three are distinguished members of the scientific, research, and public health communities appointed by the President to advise him...
Phase III Trial of Cabozantinib and Atezolizumab vs Sorafenib in Advanced Hepatocellular Carcinoma
As reported in The Lancet Oncology by Robin Kate Kelley, MD, and colleagues, the phase III COSMIC-312 trial has shown improved progression-free survival with cabozantinib plus atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma; interim analysis of overall survival showed...
Former NCI Director Takes Stock of His Accomplishments and Looks Ahead to the Next Challenge
After nearly 5 years as Director of the National Cancer Institute (NCI), interrupted by 7 months as Acting Commissioner for the U.S. Food and Drug Administration (FDA), Norman E. “Ned” Sharpless, MD, left his position on April 29 to concentrate on his family and contemplate his next career choice....
History of Radiation Oncology in the United States
Part 1 of this two-part report described the beginnings of radiation oncology in the United States, including many of the field’s early pioneers and the rise of associated professional societies. In part 2, we will consider the advances in technology and biology that are the foundation of modern...
Moffitt Mourns the Loss of Research Giant Robert J. Gillies, PhD
Moffitt Cancer Center and the global research community have lost a great leader, scientist, and collaborator. Robert J. Gillies, PhD, died on June 7 after an extended illness. He was 69 years old. His recruitment in 2008 elevated Moffitt’s scientific stature, and his vision and work over the past...
Francesca M. Gany, MD, MS, Receives Excellence in Health Care Award From United Hospital Fund
Francesca M. Gany, MD, MS, Chief of the Immigrant Health and Cancer Disparities Service at Memorial Sloan Kettering Cancer Center in New York, was awarded a 2022 Excellence in Health Care Award by the United Hospital Fund. The award was established in 2019 to honor extraordinary personal...
Cleveland Clinic Appoints Alex A. Adjei, MD, PhD, as Chair of Taussig Cancer Institute
Alex A. Adjei, MD, PhD, is the new Chair of Cleveland Clinic Taussig Cancer Institute. Previously, he served as Consultant in Oncology, Professor of Oncology and Professor of Pharmacology at Mayo Clinic and Mayo Clinic College of Medicine and Science in Rochester, Minnesota. Dr. Adjei also oversaw ...
Inspired by the TV Show M*A*S*H, Lori Wilson, MD, FACS, Achieves Many Firsts as a Leader in Oncology
Lori Wilson, MD, FACS, Chief of Surgical Oncology, Associate Dean of Faculty Development and Diversity, and former Program Director of the General Surgical Residency at Howard University Hospital, is the first woman to hold the position of Division Chief as well as the first tenured Professor of...
Addition of Atezolizumab to Neoadjuvant Anti-HER2 Therapy and Chemotherapy in HER2-Positive Breast Cancer: IMpassion050
As reported in the Journal of Clinical Oncology by Jens Huober, MD, and colleagues, the phase III IMpassion050 trial showed no significant improvement in pathologic complete response rate with the addition of atezolizumab to neoadjuvant pertuzumab/trastuzumab and chemotherapy in patients with...
Strides Are Being Made in the Treatment of Brain Metastases From Breast Cancer
New drugs for HER2-positive breast cancer are able to overcome some of the obstacles that have made brain metastases challenging to treat, according to Mark Pegram, MD, the Susy Yuan-Huey Hung Professor of Oncology at Stanford University School of Medicine in California, who described the promising ...
Addition of Olaparib to Durvalumab in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma
As reported in the Journal of Clinical Oncology by Jonathan E. Rosenberg, MD, and colleagues, the phase II BAYOU trial has shown no improvement in progression-free survival with the addition of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib to the anti–PD-L1 agent durvalumab in...
New Consensus-Based Guidance on Managing Cancer Pain in Patients With Opioid Use Disorder or Opioid Misuse
Opioids are a cornerstone of cancer pain management, but there is a lack of consensus on how to treat pain patients with cancer who also have struggled with opioid use disorder or prescription opioid misuse. In a study published by Fitzgerald Jones et al in JAMA Oncology, researchers outlined...
Lisocabtagene Maraleucel as Second-Line Treatment for Relapsed or Refractory Large B-Cell Lymphoma: TRANSFORM Trial
As reported in The Lancet by Manali Kamdar, MD, and colleagues, an interim analysis of the phase III TRANSFORM trial has shown significantly improved event-free survival with second-line lisocabtagene maraleucel vs standard-of-care salvage immunochemotherapy followed by autologous hematopoietic...
Rucaparib Maintenance Improves Progression-Free Survival in Patients With Newly Diagnosed Advanced Ovarian Cancer Who Responded to Platinum-Based Therapy
Maintenance therapy with the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib led to a significant improvement in progression-free survival compared with placebo in patients with newly diagnosed advanced ovarian cancer who responded to first-line platinum-based chemotherapy. The...
Study Finds COVID-19 Vaccines Are Safe for Patients Treated With Immune Checkpoint Inhibitors for Lung Cancer
Patients with cancer have received priority status to receive COVID-19 vaccinations, but limited data are available regarding the safety and efficacy of the vaccines for patients treated with immune checkpoint inhibitors for lung cancer. Now, a new study published by Hibino et al in the Journal of...
Addition of Trastuzumab/Pertuzumab to Perioperative FLOT Chemotherapy in HER2-Positive Esophagogastric Adenocarcinoma
In the German phase II PETRARCA trial of the AIO EGA Study Group, reported in the Journal of Clinical Oncology, Hofheinz et al found that the addition of trastuzumab and pertuzumab to perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) improved both the pathologic complete...
18 Million Cancer Survivors in the United States, New Report Shows
A new report led by researchers at the American Cancer Society (ACS) in collaboration with the National Cancer Institute (NCI) shows more than 18 million Americans (8.3 million males and 9.7 million females) with a history of cancer were living in the United States as of January 1, 2022, with a...
Maxwell Oluwole Akanbi, MD, PhD, on Lung Cancer: The Effect of Screening on the Incidence of Advanced Disease
Maxwell Oluwole Akanbi, MD, PhD, of McLaren Regional Medical Center, discusses the study he conducted, using the SEER database, to evaluate the impact of lung cancer screening recommendations on low-dose CT scanning. The data suggest that guidelines from the U.S. Preventive Services Task Force led...
Chemicals in Personal Care Products May Increase Breast Cancer Risk in Black Women
The group of compounds called parabens, which are found in widely used hair and personal care products, may increase breast cancer risk in Black women—more so than in White women—according to a study presented at ENDO 2022, the Endocrine Society’s Annual Meeting. One in eight women in the United...
Nivolumab in Combination With Chemotherapy and in Combination With Ipilimumab in Advanced Esophageal Squamous Cell Carcinoma
On May 27, 2022, nivolumab was approved for use in combination with fluoropyrimidine- and platinum-based chemotherapy and in combination with ipilimumab for the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma.1 Supporting Efficacy Data Approval was based on...
History of Radiation Oncology in the United States
Radiation therapy has long been one of the three pillars of cancer therapy—surgery, chemotherapy, and radiotherapy—only recently joined by what is widely considered a fourth pillar, immunotherapy. In part 1 of this two-part report, we trace the beginnings of radiation oncology in the United...
Cancer and War in Ukraine: How the World Can Help Win This Battle
In Ukraine, with a population of about 44 million, there are more than 1.3 million patients with cancer. Approximately 160,000 new cases of cancer are diagnosed each year.1 In almost every region, there are local cancer centers; specialized oncologic centers are located in large cities. In Kyiv,...
Invest in the Unexpected: Basic Research Enterprise Needs Adequate Funding to Foster Treatment Innovation
The National Institutes of Health (NIH) now stands as the largest single public funder of biomedical research in the world.1 The FY2022 Consolidated Appropriations Act (H.R. 2471), signed into law in March, increases biomedical research funding by nearly 5%, and it provides a total of $45 billion...
Cancer Death Rates Among Black People Declined Over Time but Remain Higher Than Other Racial and Ethnic Groups
From 1999 to 2019, rates of cancer deaths declined steadily among Black people in the United States. Nevertheless, in 2019, Black people still had considerably higher rates of cancer death than people in other racial and ethnic groups, a large epidemiologic study has found. The study was led by...
American Cancer Society Investigators Present Studies on COVID-19 Pandemic, Racial/Ethnic Disparities, and Coverage for Genomic Testing
Investigators at the American Cancer Society presented results of several studies during poster sessions at the 2022 ASCO Annual Meeting. Summaries of a few of these studies are provided here. COVID-19 and Cancer Mortality According to a new study led by researchers at the American Cancer Society,...
Expert Point of View: Thomas Seufferlein, MD
Thomas Seufferlein, MD, Professor of Medicine at Ulm University Hospital in Germany, found the data from the NOTABLE trial1 encouraging and “clinically interesting.” However, he suggested the study’s design did not allow the EGFR inhibitor to be optimally tested. The NOTABLE trial is based on a...
100% Complete Response Rate in 14 Patients With Rectal Cancer Treated With Neoadjuvant Dostarlimab-gxly
In a study of 18 patients with locally advanced mismatch repair–deficient (dMMR) rectal cancer, 6 months of neoadjuvant treatment with the anti–PD-1 agent dostarlimab-gxly alone led to clinical complete responses in 100% of the study’s first 14 patients.1 These results were presented at the 2022...
Mismatch in Breast Cancer Trial Results and Real-World Outcomes Based on Treatment Discontinuation
New research published by Zeng et al in JNCCN—Journal of the National Comprehensive Cancer Network raises issues with clinical trial findings that show adjuvant hormone therapy–related hot flashes predict better treatment outcomes among patients with estrogen receptor–positive breast cancer. The...
Study Identifies Three-Gene Signature That May Predict Response to Selinexor in Patients With Multiple Myeloma
Researchers have, for the first time, identified genes that may predict response to a therapy for a blood cancer that can have serious side effects for some patients. The therapy, selinexor, is part of the treatment armamentarium for multiple myeloma, but the ability to target its use to patients...
Cabozantinib and Atezolizumab for Patients With Progressive Metastatic Castration-Resistant Prostate Cancer Post–Hormonal Therapy
As reported in The Lancet Oncology by Neeraj Agarwal, MD, and colleagues, findings in the expansion cohort of the phase Ib COSMIC-021 trial indicate activity of the combination of cabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer whose disease progressed ...
Four New Teams Receive $100M to Take on Cancer's Toughest Challenges
Representing a total investment of $100 million, the following teams are the first to be funded through the partnership between Cancer Research UK and the National Cancer Institute in the United States. These teams join the Cancer Grand Challenges community, which now unites more than 700...
Are Virtual Frailty Assessments for Older Patients With Hematologic Malignancies Effective?
According to a study published by DuMontier et al in the journal Blood Advances, frailty assessments—geriatric exams considered essential to predicting health outcomes in older adults with cancer—are both safe and feasible when conducted virtually for patients with blood cancers. While providers...
Targeted Therapy Emavusertib Shows Activity in Patients With MDS or AML With Specific Mutations
Mutations in SF3B1 and U2AF1 can drive overexpression of activated IRAK4—which regulates inflammation and promotes cancer cell growth and survival—and are associated with a poor prognosis for patients with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Emavusertib is a...
Allogeneic CAR T-Cell Therapy for Relapsed or Refractory T-Cell Lymphoma
Patients with relapsed or refractory T-cell lymphoma have limited treatment options. Chimeric antigen receptor (CAR) T-cell therapy has been challenging in these patients because of the state of their T cells. CTX130 is an allogeneic CAR T-cell therapy targeting CD70 on cancerous T cells, offering...
Ralph Lauren Corporate Foundation Announces $25 Million Commitment to Five U.S. Cancer Centers to Help Reduce Disparities in Cancer Care in Underserved Communities
The Ralph Lauren Corporate Foundation recently announced it will provide $25 million in new grant funding to expand or establish five Ralph Lauren cancer centers, aimed at reducing disparities in cancer care and access across underserved communities in the United States. The funding will benefit...
The Mark Foundation for Cancer Research Appoints Ryan Schoenfeld, PhD, as Chief Executive Officer
The Mark Foundation for Cancer Research, which actively partners with scientists, research institutions, and philanthropic organizations around the world to accelerate research in the prevention, diagnosis, and treatment of cancer, recently announced that Ryan Schoenfeld, PhD, has been appointed...
Jennifer Willcox, JD, Named Senior Vice President, General Counsel, and Chief Governance Officer at Dana-Farber
After a nationwide search, Jennifer Willcox, JD, has been named Senior Vice President, General Counsel, and Chief Governance Officer at Dana-Farber Cancer Institute. In this role, Ms. Willcox has overall responsibility for the legal and board governance function of Dana-Farber. She will serve on...
Annual Meeting of the Moroccan Cancer Society: An Opportunity for Young Cancer Researchers to Evolve
The Moroccan Cancer Society (MCS; Société Marocaine de Cancérologie/https://smc.ma) was created in 1992 by a group of Moroccan medical and radiation oncologists, surgeons, and pathologists who had led the field in the 1980s. To date, this scientific society has more than 350 members practicing in...
Cemiplimab-rwlc Improves Overall Survival vs Chemotherapy in Recurrent Cervical Cancer After First-Line Platinum-Based Chemotherapy
As reported in The New England Journal of Medicine by Krishnansu S. Tewari, MD, of the Division of Gynecologic Oncology, University of California, Irvine, and colleagues, the phase III EMPOWER-Cervical1/GOG-3016/ENGOT-cx9 trial has shown improved overall survival with cemiplimab-rwlc vs...
T-DXd Improves Progression-Free Survival vs T-DM1 in Metastatic HER2-Positive Breast Cancer
As reported in The New England Journal of Medicine by Javier Cortés, MD, PhD, of the International Breast Cancer Center, Barcelona, and colleagues, the phase III DESTINY-Breast03 trial has shown significantly prolonged progression-free survival with fam-trastuzumab deruxtecan-nxki (T-DXd) vs...
Manali I. Patel, MD, MPH, on Equitable, Value-Based Care: The Effectiveness of Community Health Worker–Led Interventions
Manali I. Patel, MD, MPH, of Stanford University School of Medicine, discusses clinical trial findings on the best ways to integrate community-based interventions into cancer care delivery for low-income and minority populations. Such interventions may improve quality of life and patient activation ...
Capecitabine Plus Temozolomide vs Temozolomide Alone in Advanced Pancreatic Neuroendocrine Tumors
In the updated final analysis of the phase II ECOG-ACRIN E2211 trial, patients with advanced pancreatic neuroendocrine tumors experienced a significant improvement in progression-free survival with capecitabine plus temozolomide over temozolomide alone.1 Although the 5-month difference in overall...
ATHENA-MONO Trial: Rucaparib Maintenance in Newly Diagnosed Patients With Advanced Ovarian Cancer
As presented at the 2022 ASCO Annual Meeting (Abstract LBA5500) and simultaneously reported in the Journal of Clinical Oncology by Bradley J. Monk, MD, and colleagues, the phase III ATHENA-MONO trial found that maintenance rucaparib significantly improved progression-free survival vs placebo among...
Three-Arm First-Line Chemoimmunotherapy Study in Patients With Metastatic Pancreatic Cancer
Combinations of chemotherapy and immunotherapy showed activity in patients with metastatic pancreatic cancer, according to findings from a national, randomized clinical trial led and sponsored by the Parker Institute for Cancer Immunotherapy. The results of the small trial were presented by Padrón...
Did the ACA’S Medicaid Expansion Affect Cancer Clinical Trial Enrollment?
Researchers from the SWOG Cancer Research Network, a clinical trials group funded by the National Cancer Institute (NCI), found that the Affordable Care Act’s (ACA) expansion of Medicaid insurance in 2014 was followed by a significant increase in the proportion of patients enrolling in SWOG trials...
Study Shows Children Whose Parents Have a Cancer History Have Increased Unmet Economic Needs in Food, Housing, and Transportation
In a new large study led by researchers at the American Cancer Society, findings showed that parental cancer is associated with a greater likelihood of family-level food insecurity, financial worry about housing costs and other monthly bills, and transportation barriers to medical care for children ...
'Unprecedented' 100% of First 14 Untreated Patients With Rectal Cancer Respond to PD-1 Blocker Dostarlimab-gxly
Rarely, if ever, has one abstract presented at the ASCO Annual Meeting warranted its own session—but that happened with a small but mighty study from Memorial Sloan Kettering. In a study of patients with locally advanced mismatch repair–deficient (dMMR) rectal cancer, 6 months of treatment with the ...
Study Finds High-Dose Ifosfamide Superior to Other Standard-of-Care Treatments in Recurrent and Primary Refractory Ewing Sarcomas
Use of high-dose ifosfamide was found to be superior for treating recurrent and primary refractory Ewing sarcomas compared with three other standard-of-care treatments used for the disease, according to research presented by McCabe et al during the Plenary Session at the 2022 ASCO Annual Meeting...
Study Reveals Racial Disparities in Guideline-Concordant Care for Patients With Early-Onset Colorectal Cancer
In a large national study, Black patients diagnosed with early-onset colorectal cancer received worse and less timely care than their White counterparts. Differences in health insurance coverage type, a modifiable factor, according to the findings, accounted for the largest identified contributor...
New Report Shows COVID-19 Pandemic Increased Cancer-Related Deaths in the United States
According to a new study led by researchers at the American Cancer Society, the COVID-19 pandemic increased the number of cancer-related deaths by 3.2% in the United States from 2019 to 2020. Compared to 2019, the monthly cancer-related mortality rate was higher in April 2020, when health-care...
